Revenue Growth Driven by Core Portfolio
Total revenue increased 5.4% YoY to $14.45B in Q1 2026 from $13.72B in Q1 2025, suggesting continued demand recovery across Pfizer's product portfolio beyond the COVID-era peak.
PFIZER INC is expected to release its Q2 2026 10-Q filing in the upcoming earnings season. Last quarter: Pfizer reported Q1 2026 revenue of $14.45B (+5.4% YoY), but net income declined 9.4% to $2.69B as cost of revenue surged 24.7%, compressing margins despite improved operating cash flow of $2.62B.
Drawn from management commentary in the Q1 2026 10-Q:
Total revenue increased 5.4% YoY to $14.45B in Q1 2026 from $13.72B in Q1 2025, suggesting continued demand recovery across Pfizer's product portfolio beyond the COVID-era peak.
Cost of revenue jumped 24.7% YoY to $3.55B from $2.85B, significantly outpacing revenue growth of 5.4% and indicating rising manufacturing costs, product mix shifts, or inventory-related charges that compressed gross margins.
SG&A expenses declined 2.3% YoY to $2.96B from $3.03B, reflecting ongoing cost-reduction initiatives that partially mitigated the impact of higher production costs on operating income.
Revenue
$14.45B
++5.37% YoY
EPS (Basic)
$0.47
-9.62% YoY
Add PFE to your watchlist to get the AI analysis in your inbox within minutes of the 10-Q filing.